FOSTER CITY, CA--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced positive topline results from its pivotal Phase 3 MARCH study evaluating LIVMARLI® (maralixibat) oral solution in 93 patients with progressive familial...
Art Pappas will speak on "Later Stage Venture Funding" at the University of North Carolina at Chapel Hill's Technology Commercialization Workshop in Chapel Hill.
News | 10. 21. 2010
